CA1287050C - Derives de purine antiviraux - Google Patents

Derives de purine antiviraux

Info

Publication number: CA1287050C
Authority: CA; Canada
Prior art keywords: amino; compound; purine; formula; physiologically acceptable
Prior art date: 1982-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000438902A

Other languages

English (en)

Inventor

Howard J. Schaeffer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wellcome Foundation Ltd

Original Assignee

Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-10-14

Filing date

1983-10-13

Publication date

1991-07-30

1983-07-28 Priority claimed from GB838320309A external-priority patent/GB8320309D0/en

1983-10-13 Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd

1986-06-27 Priority to CA000512737A priority Critical patent/CA1308714C/fr

1991-07-30 Application granted granted Critical

1991-07-30 Publication of CA1287050C publication Critical patent/CA1287050C/fr

2008-07-30 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000000840 anti-viral effect Effects 0.000 title abstract description 6
229940083251 peripheral vasodilators purine derivative Drugs 0.000 title description 2
125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 55
150000003839 salts Chemical class 0.000 claims abstract description 44
238000000034 method Methods 0.000 claims abstract description 41
150000002148 esters Chemical class 0.000 claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
-1 compound salts Chemical class 0.000 claims abstract description 10
241001529453 unidentified herpesvirus Species 0.000 claims abstract description 4
238000002360 preparation method Methods 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 48
230000008569 process Effects 0.000 claims description 33
OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 claims description 30
238000009472 formulation Methods 0.000 claims description 30
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 20
229960004150 aciclovir Drugs 0.000 claims description 20
239000007788 liquid Substances 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 13
239000003826 tablet Substances 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
241001465754 Metazoa Species 0.000 claims description 11
239000002585 base Substances 0.000 claims description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 9
125000004429 atom Chemical group 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 9
239000002775 capsule Substances 0.000 claims description 8
238000011321 prophylaxis Methods 0.000 claims description 8
239000008187 granular material Substances 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
125000002252 acyl group Chemical group 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000000843 powder Substances 0.000 claims description 6
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 6
239000003054 catalyst Substances 0.000 claims description 5
239000003153 chemical reaction reagent Substances 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 4
239000000839 emulsion Substances 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
229910052763 palladium Inorganic materials 0.000 claims description 4
239000002243 precursor Substances 0.000 claims description 4
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 4
230000003612 virological effect Effects 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 3
IRUNKQSGDBYUDC-UHFFFAOYSA-N diethoxymethyl acetate Chemical compound CCOC(OCC)OC(C)=O IRUNKQSGDBYUDC-UHFFFAOYSA-N 0.000 claims description 3
239000012458 free base Substances 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 3
235000010288 sodium nitrite Nutrition 0.000 claims description 3
LGBSUXWZGHNQPL-UHFFFAOYSA-N 9-(2-aminoethoxymethyl)purin-2-amine Chemical compound N1=C(N)N=C2N(COCCN)C=NC2=C1 LGBSUXWZGHNQPL-UHFFFAOYSA-N 0.000 claims description 2
125000004423 acyloxy group Chemical group 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 7
238000004519 manufacturing process Methods 0.000 claims 3
BSFGGUCAZGXDGK-UHFFFAOYSA-N 2-[(2-amino-6-chloropurin-9-yl)methoxy]ethanol Chemical compound NC1=NC(Cl)=C2N=CN(COCCO)C2=N1 BSFGGUCAZGXDGK-UHFFFAOYSA-N 0.000 claims 1
ZGBDUUGWUHBQNX-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethyl acetate Chemical compound N1=C(N)N=C2N(COCCOC(=O)C)C=NC2=C1 ZGBDUUGWUHBQNX-UHFFFAOYSA-N 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
241000175212 Herpesvirales Species 0.000 claims 1
125000005103 alkyl silyl group Chemical group 0.000 claims 1
238000005984 hydrogenation reaction Methods 0.000 claims 1
239000004480 active ingredient Substances 0.000 description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000007787 solid Substances 0.000 description 11
239000004615 ingredient Substances 0.000 description 10
239000003921 oil Substances 0.000 description 8
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
241000700159 Rattus Species 0.000 description 7
239000000047 product Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000000969 carrier Substances 0.000 description 6
239000006071 cream Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000006072 paste Substances 0.000 description 6
150000003212 purines Chemical class 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
239000003925 fat Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
208000009889 Herpes Simplex Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
108010093894 Xanthine oxidase Proteins 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
206010019973 Herpes virus infection Diseases 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
102100033220 Xanthine oxidase Human genes 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
125000003435 aroyl group Chemical group 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
235000017168 chlorine Nutrition 0.000 description 2
229940060038 chlorine Drugs 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000001117 sulphuric acid Substances 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
125000004149 thio group Chemical group *S* 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
230000036325 urinary excretion Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
XFEQOLXBMLXKDE-UHFFFAOYSA-N 2-(acetyloxymethoxy)ethyl acetate Chemical compound CC(=O)OCCOCOC(C)=O XFEQOLXBMLXKDE-UHFFFAOYSA-N 0.000 description 1
KLKBZOUQDOSRIC-UHFFFAOYSA-N 2-[(2-acetamido-6-sulfanylidene-3h-purin-9-yl)methoxy]ethyl acetate Chemical compound N1C(NC(=O)C)=NC(=S)C2=C1N(COCCOC(C)=O)C=N2 KLKBZOUQDOSRIC-UHFFFAOYSA-N 0.000 description 1
MKTTXCDPHPEDCL-UHFFFAOYSA-N 2-[(2-amino-6-chloropurin-9-yl)methoxy]ethyl benzoate Chemical compound C12=NC(N)=NC(Cl)=C2N=CN1COCCOC(=O)C1=CC=CC=C1 MKTTXCDPHPEDCL-UHFFFAOYSA-N 0.000 description 1
GQJJWENQMWRFAT-UHFFFAOYSA-N 2-[2-(chloromethoxy)ethyl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCOCCl)C(=O)C2=C1 GQJJWENQMWRFAT-UHFFFAOYSA-N 0.000 description 1
OFRBPRKMMHGTTN-UHFFFAOYSA-N 2-[2-[(2-aminopurin-9-yl)methoxy]ethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCOCN1C=NC2=CN=C(N)N=C21 OFRBPRKMMHGTTN-UHFFFAOYSA-N 0.000 description 1
150000005019 2-aminopurines Chemical class 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
108091023020 Aldehyde Oxidase Proteins 0.000 description 1
102100036826 Aldehyde oxidase Human genes 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
239000004358 Butane-1, 3-diol Substances 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
101150005343 INHA gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
238000007098 aminolysis reaction Methods 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000006052 feed supplement Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical compound CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
DPWRVXSEHRVTLC-UHFFFAOYSA-N n-(9-acetyl-6-sulfanylidene-3h-purin-2-yl)acetamide Chemical compound N1C(NC(=O)C)=NC(=S)C2=C1N(C(C)=O)C=N2 DPWRVXSEHRVTLC-UHFFFAOYSA-N 0.000 description 1
NCCHARWOCKOHIH-UHFFFAOYSA-N n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1 NCCHARWOCKOHIH-UHFFFAOYSA-N 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008251 pharmaceutical emulsion Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N purine-6-thione Natural products S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
238000009491 slugging Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000003351 stiffener Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000005418 vegetable material Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000438902A 1982-10-14 1983-10-13 Derives de purine antiviraux Expired - Fee Related CA1287050C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000512737A CA1308714C (fr)	1982-10-14	1986-06-27	Composes antiviraux

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US43439382A	1982-10-14	1982-10-14
US434,393		1982-10-14
GB8320309		1983-07-28
GB838320309A GB8320309D0 (en)	1983-07-28	1983-07-28	Antiviral compounds

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000512737A Division CA1308714C (fr)	1982-10-14	1986-06-27	Composes antiviraux

Publications (1)

Publication Number	Publication Date
CA1287050C true CA1287050C (fr)	1991-07-30

Family

ID=26286697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000438902A Expired - Fee Related CA1287050C (fr)	1982-10-14	1983-10-13	Derives de purine antiviraux

Country Status (1)

Country	Link
CA (1)	CA1287050C (fr)

1983
- 1983-10-13 CA CA000438902A patent/CA1287050C/fr not_active Expired - Fee Related

Legal Events

Date	Code	Title	Description
1994-02-01	MKLA	Lapsed

Publication	Publication Date	Title
EP0108285B1 (fr)	1988-04-20	Dérivés de purine antiviraux
KR880002276B1 (ko)	1988-10-21	항비루스성 화합물의 제조방법
US4714701A (en)	1987-12-22	Antiviral compounds
CA1208637A (fr)	1986-07-29	Derives de la 9-(2-hydroxyethoxymethyl)guanine
US4609662A (en)	1986-09-02	Method for using purine derivatives
US4544634A (en)	1985-10-01	Method of producing acyclovir
US4695570A (en)	1987-09-22	Antiviral compound use
US4649140A (en)	1987-03-10	Purine derivatives
EP0366385B1 (fr)	1993-06-09	Dérivés de guanine ayant une activité anti-virale et leurs sels pharmaceutiquement acceptables
US5079252A (en)	1992-01-07	Therapeutic compounds
CA1287050C (fr)	1991-07-30	Derives de purine antiviraux
US5059604A (en)	1991-10-22	2-amino purine derivatives
US4745119A (en)	1988-05-17	Method for using purine derivatives
EP0203736B1 (fr)	1989-11-23	Composés antiviraux
IE44708B1 (en)	1982-03-10	Esters of hydroxyalkoxylkyl purines, their preparation, and pharmaceutical compositions containing them
EP0158513A2 (fr)	1985-10-16	Composés antiviraux
GB1561380A (en)	1980-02-20	Esters of hydroxyalkoxyalkyl purines their preparation and pharmaceutical compositions containing them
JPS61277686A (ja)	1986-12-08	新規なプリン誘導体およびその製造法ならびにその製剤組成物
NZ217312A (en)	1988-02-29	Purine derivatives and pharmaceutical compositions
CS244679B2 (en)	1986-08-14	Production method of anti virus effective compound
DD221179A5 (de)	1992-05-07	Kombinierter elektromagnetischer und - akustischer wandler fuer fernraeumgeraete